Vir Biotech's VIR-7831 Maintains Activity Against California Variant Of COVID-19 Infection

Monday, 5 April 2021, 15:08:53
Vir Biotechnology Inc (NASDAQ: VIR ) has announced new preclinical data of VIR-7831, the company's investigational monoclonal antibody (mAb) against SARS-CoV-2. The new data showed that the antibody maintains its neutralizing activity against a mutation in the receptor-binding domain (RBD) of SARS-CoV-2, called L452R, found in the California variant (B.1.427/B.1.429). Data from 43 … Full story available on Benzinga.com
— Benzinga

GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug

Friday, 26 March 2021, 17:42:51
GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology Inc. (NASDAQ: VIR ) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with mild-to-moderate COVID-19 who are at risk for a severe worsening of their condition. What Happened: The VIR-7831 project began in April 2020 when the companies began a partnership to develop solutions to combat coronaviruses. The preclinical data suggests VIR-7831 could potentially block viral entry into healthy … Full story available on Benzinga.com
— Benzinga

Can Vir Biotechnology’s share price outperform the biotech theme?

Thursday, 18 March 2021, 13:15:00
Vir Biotech’s share price is the latest stock to see uplift following promising COVID-19 vaccine results.
— CMC Markets

Barclays Stick to Their Buy Rating for Vir Biotechnology By Investing.com

Saturday, 13 March 2021, 02:10:39
Barclays Stick to Their Buy Rating for Vir Biotechnology
— Investing.com

Herbert Virgin Sells 2,340 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Saturday, 13 March 2021, 00:13:32
Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Herbert Virgin sold 2,340 shares of the firm’s stock in a transaction on Wednesday, March 10th. The stock was sold at an average price of $48.00, for a total value of $112,320.00. Following the transaction, the executive vice president now owns 76,540 shares in the company, valued at $3,673,920. The […]
— Watchlist News